Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the US Food and Drug Administration for Dapagliflozin Tablets in 5mg and 10mg strengths. The regulatory milestone marks a significant addition to the company's diabetes treatment portfolio.

FDA Approval Details

The approved Dapagliflozin Tablets are indicated for treating adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Additionally, the medication is approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus who have either established cardiovascular disease or multiple cardiovascular risk factors.

Strategic Portfolio Enhancement

This FDA approval significantly strengthens Biocon's expanding diabetes portfolio, which spans multiple therapeutic approaches including oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides. The comprehensive portfolio demonstrates the company's integrated approach to addressing the evolving needs of people living with diabetes globally.

Manufacturing Standards

Dapagliflozin Tablets will be manufactured at Biocon's FDA-approved facilities, ensuring compliance with global quality and regulatory standards. The company's established manufacturing infrastructure supports its ability to deliver high-quality pharmaceutical products to international markets.

Regulatory Communication

Biocon Limited formally notified stock exchanges BSE Limited and National Stock Exchange of India Limited about this development through its subsidiary Biocon Pharma Limited. The announcement was made in compliance with regulatory requirements for material developments.

Global pharmaceutical major Lupin Limited has been awarded the prestigious Great Place To Work® certification for 2026-27, positioning itself among select pharmaceutical companies to achieve this globally recognized workplace excellence standard. The certification was announced on April 07, 2026, following a comprehensive evaluation spanning all of Lupin's subsidiaries and geographical locations.

Recognition Through Employee Engagement

The Great Place To Work® certification, widely regarded as the gold standard for workplace excellence, was earned through significant employee participation and feedback. The evaluation process demonstrated strong workforce engagement across Lupin's global operations.

Leadership Perspective on Workplace Culture

Yashwant Mahadik, President – Global Human Resources at Lupin, emphasized the significance of this achievement in reflecting the company's inclusive and values-driven workplace culture. The recognition highlights how employees across different geographies feel respected, valued, and empowered to perform at their best. The company remains committed to continuously enhancing the employee experience across all locations while further strengthening its organizational culture.

Investment in Human Capital

Lupin's commitment to its workforce is demonstrated through substantial investments in employee development and benefits. The company maintains a permanent workforce of over 24,000 professionals across various functions and geographical locations.

Global Pharmaceutical Presence

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed across over 100 markets worldwide. The company specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong market position in India and the United States across multiple therapy areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.

The company's operational infrastructure includes 15 state-of-the-art manufacturing sites and 7 research centers globally. Through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions – the organization remains committed to improving patient health outcomes while maintaining its focus on workplace excellence and employee satisfaction.